As of April 2012 OCT is proud to announce that it has commenced participation in a global Atrial fibrillation study. OCT will be recruiting 600 patients at 30 sites in Russia, and the study will conclude in 2020. The study will include patients newly diagnosed with non-valvular atrial fibrillation aged 18 years or older. Overall there will be about 2,200 sites including hospitals, anticoagulant clinics, specialists and general practice settings in up to 60 countries in 5 regions of the world. This is a phase IV clinical study investigating the patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in non-valvular atrial fibrillation (AF) patients.
Atrial fibrillation (AF) is the most common cardiac arrhythmia and affects approximately 1-2% of the population globally. It is estimated that 6 million people in Europe and 2.7
Million people in the USA suffer from AF. The lifetime risk for development of AF is one in four for those over the age of 40 years. The prevalence of AF rises with advancing age, increasing from less than 1% in those below 60 years of age to nearly 20% in those 85 years of age and older. The overall prevalence of AF is also increasing; hospital admissions for AF have increased 60% over the past 20 years. The prevalence of AF is estimated to double by 2050 due to the aging of the world’s population.
Thromboembolic complications – particularly stroke – are a major cause of morbidity and mortality in patients with AF. Most cases of stroke in patients with AF are the result of embolization of a left atrial thrombus, and particularly from the left atrial appendage. Patients with AF have a four- to five-fold higher risk for stroke than those without AF.
OCT approved the study at one of the Independent Ethics Committees in Russia. The study is being conducted for a top 10 pharmaceutical company.